Navigation Links
Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary
Date:11/13/2007

of the webcast will be available on Isis' web site for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for a wide variety of diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of mipomersen in treating patients with high cholesterol. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
(Date:8/29/2014)... Pa. , Aug. 29, 2014  Unilife Corporation ... UNS) announced today that it intends to release its ... year ended June 30, 2014 after market trading ends ... has scheduled a conference call for 4:30 p.m. U.S. ... 2014 at 6:30 a.m. AEST), to review the Company,s financial ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
(Date:8/30/2014)... 30, 2014 Ticket Down reports that ... exhibition match next Saturday at Levi's Stadium. The summer ... fans in the United States due to the fact that so ... every major city. Many of these games were practice games ... past summer. , Levi’s Stadium is a brand new facility that ...
(Date:8/30/2014)... Dayton, OH (PRWEB) August 30, 2014 United ... school’s first fully online degree, the Master of Theological Studies ... completed in 2-3 years, is designed for students who wish ... deepen their understanding and capacity to serve the Church and ... this degree, but now they can attend classes from any ...
(Date:8/30/2014)... Patients suffering from vitiligo can now ... new review published by Daily Gossip. , Vitiligo ... there is no wonder that numerous sufferers search for ... Treatment is one of the most appreciated such methods ... to stop the spread of this disorder immediately, while ...
(Date:8/30/2014)... Daily Gossip magazine reveals in its "Panic ... attacks under control with a simple and efficient method. ... this new method as an anxiety recovery program which ... general anxiety related disorders. , What makes this ... it can be accessed by users from the comfort ...
(Date:8/30/2014)... The Plastic Surgery Group (PSG) is ... even in the U.S. to provide clients with Vanquish, ... patients’ waists with deep-tissue heating. , Unlike Cryotherapy which ... is more inclusive to target large sections of desired ... panels about one inch away from their body while ...
Breaking Medicine News(10 mins):Health News:Mexico vs. Chile Tickets at Levi's Stadium in Santa Clara, CA: TicketDown.com Offers Promo Code for Mexico vs. Chile Exhibition Game on September 6th 2Health News:United Theological Seminary Announces First Fully Online Degree 2Health News:Natural Vitiligo Treatment Review Exposes Fast Method for Skin Repigmentation 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2
... - Notification of Year End,2007 Earnings Webcast and Conference ... Year End 2007 Earnings Webcast and Conference Call ... listen to this Webcast and Conference Call event, please ... in the live conference call please dial into either,(604) ...
... announced today,that it has initiated coverage on leading Australian ... hand and royalty,revenue alone are equal to roughly US$0.94 ... DCF value for ART621 and you have a premium,of ... without assigning any,value to their current pre-clinical pipeline which ...
... International,Inc. (Nasdaq: CHDX ) (the ,Company,) today announced ... split of all shares of,the Company,s Common Stock, par ... Stockholders of record as of the close of business ... Common Stock for each,share owned on that date in ...
... 1418 passed by full Senate, moves to House, ... allowing the state Medicaid program to expend moneys to ... approved,by a vote of 27 to 3., Currently, ... doesn,t,cover smoking cessation programs in the state,s Medicaid program, ...
... acuity may actually improve , , TUESDAY, March 18 (HealthDay ... head-and-neck cancer patients experience decreases in their physical quality ... of life, says a U.S. study. , In ... head and neck cancer treatment such as feeding tube ...
... scientists have been proclaiming the benefits of exercise. Studies ... in number, examining many health problems ranging from cancer ... Now, a University of Missouri researcher has found direct ... Disease Control that a reduction in daily physical activity ...
Cached Medicine News:Health News:Vista Partners Initiates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx) 2Health News:Chindex International, Inc. Announces Three-For-Two Stock Split 2Health News:Chindex International, Inc. Announces Three-For-Two Stock Split 3Health News:Arizona Senate Approves Smoking Cessation Treatments for State Medicaid Beneficiaries 2Health News:Head and Neck Cancer Outcomes a Mixed Bag 2Health News:Killer stairs? Taking the elevator could be worse for your body 2Health News:Killer stairs? Taking the elevator could be worse for your body 3
The VersaStep™ 5 mm and VersaStep™ PLUS Reposable system components for creating each access port are supplied in separate packages....
... Plus Long Instrument for applications ... VERSASTEP™ Plus Long Instrument with ... unique endoscopic entry device that ... It is used to establish ...
... device components are supplied sterile. , ,The ... supplied sterile in 2/3, 5, 7/8, 10 and ... combinations. They are used in conjunction with the ... radially Expandable Sleeve. The 5, 7/8, 10 and ...
BLUNTPORT Plus Single Use Converterless 5 mm - 12 mm Trocar System for Open Laparoscopy....
Medicine Products: